Abstract
Clinical significance of plasma urothelial carcinoma associated 1 (UCA1) in patients with colorectal cancer (CRC) remains unclear. This study investigated the usefulness of plasma UCA1 as a biomarker in patients with CRC. UCA1 levels were measured in the plasma and tissue from patients with CRC by quantitative polymerase chain reaction. Relationships between plasma UCA1 and clinicopathological features were examined. Plasma UCA1 levels were significantly lower in patients with CRC than in healthy volunteers. UCA1 expression in B-Raf proto-oncogene serine/threonine kinase (BRAF)-mutant CRC tissue was also lower than that in non-cancerous tissue, although it was higher in CRC with wild-type BRAF. In right-sided CRC, a lower plasma UCA1 level was associated with pT4 and BRAF mutation. In contrast, in left-sided CRC, higher plasma UCA1 was associated with pT4 and pStage 3b-4. Plasma UCA1 is a useful biomarker for CRC detection and predicting clinicopathological features, particularly BRAF mutation.
Highlights
Clinical significance of plasma urothelial carcinoma associated 1 (UCA1) in patients with colorectal cancer (CRC) remains unclear
Plasma UCA1 levels were significantly lower in 76 patients with CRC than in 20 healthy volunteers (HVs) (p=0.004, Figure 1A)
Relationships between the plasma UCA1 level and clinicopathological features in patients with CRC were examined by the median value of plasma UCA1
Summary
Clinical significance of plasma urothelial carcinoma associated 1 (UCA1) in patients with colorectal cancer (CRC) remains unclear. This study investigated the usefulness of plasma UCA1 as a biomarker in patients with CRC. Materials and Methods: UCA1 levels were measured in the plasma and tissue from patients with CRC by quantitative polymerase chain reaction. Relationships between plasma UCA1 and clinicopathological features were examined. Results: Plasma UCA1 levels were significantly lower in patients with CRC than in healthy volunteers. In right-sided CRC, a lower plasma UCA1 level was associated with pT4 and BRAF mutation. In left-sided CRC, higher plasma UCA1 was associated with pT4 and pStage 3b-4. Conclusion: Plasma UCA1 is a useful biomarker for CRC detection and predicting clinicopathological features, BRAF mutation
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call